Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial to Investigate Pelareorep in Combination with Atezolizumab for the Treatment of Cancer

Trial Profile

A Clinical Trial to Investigate Pelareorep in Combination with Atezolizumab for the Treatment of Cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Pelareorep (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms AWARE-1
  • Most Recent Events

    • 17 Sep 2018 New trial record
    • 06 Sep 2018 According to an Oncolytics Biotech media release, the company has entered into a Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd to supply atezolizumab (Tecentriq) for use in the companys clinical development program.The company plans to incorporate this anti-PD-L1 cancer immunotherapy into the clinical program immediately.Under this agreement, Roche will supply atezolizumab for this proposed clinical trial with both parties having access to the clinical data.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top